[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HRP20192336T1 - Derivati imidazotiadiazola i imidazopirazina kao inhibitori proteazom aktiviranog receptora 4 (par4) za liječenje agregacije trombocita - Google Patents

Derivati imidazotiadiazola i imidazopirazina kao inhibitori proteazom aktiviranog receptora 4 (par4) za liječenje agregacije trombocita Download PDF

Info

Publication number
HRP20192336T1
HRP20192336T1 HRP20192336TT HRP20192336T HRP20192336T1 HR P20192336 T1 HRP20192336 T1 HR P20192336T1 HR P20192336T T HRP20192336T T HR P20192336TT HR P20192336 T HRP20192336 T HR P20192336T HR P20192336 T1 HRP20192336 T1 HR P20192336T1
Authority
HR
Croatia
Prior art keywords
alkyl
halo
group
alkoxy
independently selected
Prior art date
Application number
HRP20192336TT
Other languages
English (en)
Inventor
Jacques Banville
Roger RÉMILLARD
Edward H. Ruediger
Daniel H. Deon
Marc Gagnon
Laurence DUBÉ
Julia GUY
Eldon Scott Priestley
Shoshana L. POSY
Brad D. MAXWELL
Pancras C. Wong
Michael R. Lawrence
Michael M. Miller
Original Assignee
Bristol-Myers Squibb Company
Université de Montréal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company, Université de Montréal filed Critical Bristol-Myers Squibb Company
Publication of HRP20192336T1 publication Critical patent/HRP20192336T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Claims (15)

1. Spoj sa formulom I: ili stereoizomer, tautomer, farmaceutski prihvatljiva sol ili solvat istog, gdje: WjeO; R0 je R1; Y je S ili -CR8=CR9-; R1 je nezavisno odabran od grupe koja se sastoji od: H, halo, C1-C2 alkila, ciklopropila, C1-C2 alkoksi, C1-C2 alkiltio, halo-C1-C2-alkila, koji sadrži 1 do 5 halogena, gdje je halo F ili Cl, i halo-C3-C4 cikloalkila; R8 i R9 su nezavisno odabrani od grupe koja se sastoji od: H, fluoro, kloro, C1-C3 alkila, C1-C2 alkoksi, i halo-C1-C2 alkila; pod uvjetom da najmanje jedan od R1, R8 i R9 je drugačije od H; R2 je H, X1 je odabran od grupe koja se sastoji od CH ili N; X2, X3 i X4 su nezavisno odabrani od CR3; R3 je odabran od grupe koja se sastoji od H, C1-C3 alkila, C1-C3 alkoksi, fluoro, kloro, OCF3, i halo-C1-C2-alkila, koji sadrži 1 do 5 halogena; R4 i R5 su nezavisno odabrani od H i metila; je heteroaril prsten sa 5 članova odabran od tiazola, tiadiazola, oksazola, oksadiazola, i triazola; R6 je odabran od grupe koja se sastoji od H, halo, OCF3, OCHF2, OH, CN, NO2, NR11R12, C1-C4 alkoksikarbonila, (C=O)NR11R12 i C1-C5 alkila koji je supstituiran sa 0 do 7 grupa koje su nezavisno odabrane od halo, CF3, OCF3, OH, hidroksi-C1-C4-alkila, C1-C4 alkoksi, C1-C4 alkoksi-C1-C4 alkoksi, di-C1-C4-alkilaminofenil-C1-C4-alkila, (di-C1-C4-alkoksi-C1-C4-alkil)-C1-C4-alkila, di-C1-C4-alkilamino, C3-C6-cikloalkila, i C1-C4 alkiltio, ili R6 je B-D-, gdje D je veznik, koji je odabran od: jednostruke veze, -O-, -S-,
C1-C4 alkilena koji je supstituiran sa 0 do 4 grupe koje su nezavisno odabrane od halo ili OH, C1-C4 alkilenoksi, C2-C6 alkenilena, i B je odabran iz grupe koja se sastoji od: C6-C10 arila supstituiranog sa 0 do 3 grupe nezavisno odabrane iz grupe koja se sastoji od halo, C1-C4 alkoksi, halo-C1-C4 alkoksi, C1-C4 alkila, halo-C1-C4 alkila, C3-C6 cikloalkila, cijano, nitro, NR11R12, OH, C1-C4-alkilkarboniloksi-C1-C4-alkila, hidroksi-C1-C4-alkila, COOR14, SO2R14, (C=O)NR11R12, SO2NR11R12, N(R13)(C=O)NR11R12, N(R13)(C=O)OR14, N(R13)(C=O)R14, NR13S(O)R14, NR13SO2R14, O(C=O)NR11R12, O(C=O)OR14, O(C=O)R14, (C=O)OR14, i 5-6-očlanog heteroarila, 5- do 10-očlanog heteroarila supstituiranog sa 0 do 3 grupe nezavisno odabrane iz grupe koja se sastoji od halo, C1-C4 alkoksi, halo-C1-C4 alkoksi, C1-C4 alkila, halo-C1-C4 alkila, C3-C6 cikloalkila, cijano, nitro, NR11R12, OH, C1-C4-alkilkarboniloksi-C1-C4-alkila, hidroksi-C1-C4-alkila, COOR14, SO2R14, (C=O)NR11R12, SO2NR11R12, N(R13)(C=O)NR11R12, N(R13)(C=O)OR14, N(R13)(C=O)R14, NR13S(O)R14, NR13SO2R14, O(C=O)NR11R12, O(C=O)OR14, O(C=O)R14, (C=O)OR14, 5-6-očlanog heteroarila, i (CH2)fenila, 4- do 10-očlanog heterociklila koji sadrži atome ugljika i 1 do 2 dodatna heteroatoma odabrana od N, O, i S, i supstituiranog sa 0 do 3 grupe nezavisno odabrane iz grupe koja se sastoji od halo, okso, -(CHR13)n1-5- ili 6-očlanog heteroarila supstituiranog sa 0 do 3 grupe nezavisno odabrane iz grupe koja se sastoji od halo, C1-C4 alkoksi, C1-C4 alkila, ciklopropila, CF3, OCF3, i CF2CH3; NR13S(O)R14, NR13SO2R14, -(CHR13)n1-4- do 10-očlanog-heterociklila supstituiranog sa 0 do 3 grupe nezavisno odabrane iz grupe koja se sastoji od halo, C1-C4 alkoksi, C1-C4 alkila, ciklopropila, CF3, OCF3, i CF2CH3; OH, hidroksi-C1-C4-alkila, C1-C4 alkoksi, halo-C1-C4 alkoksi, di-C1-C4-alkilamino-C1-C4-alkila, NR11R12, cijano, C1-C4 alkila, halo-C1-C4 alkila, C3-C6 cikloalkila, C1-C4-alkoksi-C1-C4-alkila, C3-C6 cikloalkil-C1-C4-alkilkarbonila, C6-C10 arilkarbonila, C1-C4-alkilkarboniloksi-C1-C4-alkila, COOR14, SO2R14, (C=O)NR11R12, SO2NR11R12, N(R13)(C=O)NR11R12, N(R13)(C=O)OR14, N(R13)(C=O)R14, O(C=O)NR11R12, O(C=O)OR14, O(C=O)R14, (C=O)OR14, i C6-C10 arila supstituiranog sa 0 do 3 grupe nezavisno odabrane iz grupe koja se sastoji od halo, C1-C4 alkoksi, C1-C4 alkila, ciklopropila, C1-C4-alkoksikarbonila, (C=O)NR11R12, CF3, OCF3, i CF2CH3; C3-C6 cikloalkila koji može sadržati nezasićenje, supstituiranog sa 0 do 3 grupe nezavisno odabrane iz grupe koja se sastoji od halo, CF3, OCF3, 5- ili 6-očlanog heteroarila, OH, okso, hidroksi-C1-C4-alkila, C6-C10 arila, COOH, okso, C1-C4-alkoksikarbonila, (C=O)NR11R12, i C1-C4 alkila; i C5-C11 spirocikloalkila koji može da sadrži nezasićenje i koji po izboru sadrži 1 do 3 heteroatoma odabrana od O, N ili S i supstituiranog sa 0 do 3 grupe nezavisno odabrane iz grupe koja se sastoji od halo, CF3, OCF3, 5- ili 6-očlanog heteroarila, OH, hidroksi-C1-C4-alkila, C6-C10 arila, i C1-C4 alkila; R11 i R12 su nezavisno, pri svakom pojavljivanju, odabrani iz grupe koja se sastoji od: H, C1-C4 alkila, halo-C1-C4-alkila, C2-C4 alkenila, -(CR14R14)n1-fenila supstituiranog sa 0 do 3 grupe nezavisno odabrane iz grupe koja se sastoji od halo, C1-C4 alkoksi, C1-C4 alkila, ciklopropila, CF3, OCF3, 5- ili 6-očlanog heteroarila, OH, OCHF2, di-C1-C4-alkilamino, i cijano, -(CHR13)n1-C3-C6-cikloalkila supstituiranog sa 0 do 3 grupe nezavisno odabrane iz grupe koja se sastoji od halo, CF3, OCF3, 5- ili 6-očlanog heteroarila, OH, hidroksi-C1-C4-alkila, i C1-C4 alkila, -(CHR13)n1-4- do 10-očlanog-heterociklila supstituiranog sa 0 do 3 grupe nezavisno odabrane iz grupe koja se sastoji od halo, CF3, OCF3, 5- ili 6-očlanog heteroarila, OH, okso, hidroksi-C1-C4-alkila, i C1-C4 alkila, -(CHR13 )n1-5- do 10-očlanog-heteroarila supstituiranog sa 0 do 3 grupe nezavisno odabrane iz grupe koja se sastoji od halo, CF3, OCF3, 5- ili 6-očlanog heteroarila, OH, hidroksi-C1-C4-alkila, i C1-C4 alkila, di-C1-C4-alkilamino-C1-C4-alkila, di-C1-C4-alkoksi-C1-C4-alkila, hidroksi-C1-C4-alkila, cijano-C1-C4-alkila, C1-C4-alkoksi-C1-C4-alkila, C1-C4-alkoksikarbonil-C1-C4-alkila, C1-C4-alkoksikarbonila, C1-C4-alkilkarbonila, fenilkarbonila; C1-C4-alkoksikarbonilamino-C1-C4-alkilkarbonila, i di-C1-C4-alkilamino-C1-C4-alkilkarbonila, alternativno, R11 i R12, kada su vezani za isti dušik, kombiniraju se da formiraju 4- do 8-očlani heterociklični prsten koji sadrži atome ugljika supstituirane sa 0 do 3 grupe nezavisno odabrane iz grupe koja se sastoji od halo, CF3, CHF2, OCF3, OCHF2, OCH2F, 5- ili 6-očlanog heteroarila, OH, okso, hidroksi-C1-C4-alkila, C1-C4 alkila i C1-C4 alkoksi, i 0 do 2 dodatna heteroatoma odabrana od N, NR13, O i S(O)p; R13 je nezavisno, pri svakom pojavljivanju, odabran iz grupe koja se sastoji od H, C1-C6 alkila i -(CH2)fenila; R14 je nezavisno, pri svakom pojavljivanju, odabran iz grupe koja se sastoji od H, C1-C6 alkila, halo-C1-C4-alkila, C1-C4-alkoksikarbonilamino i -(CH2)n1fenila supstituiranog sa 0 do 3 grupe nezavisno odabrane iz grupe koja se sastoji od halo, C1-C4 alkoksi, C1-C4 alkila, ciklopropila, CF3, OCF3, 5- ili 6-očlanog heteroarila, OH, OCHF2, di-C1-C4-alkilamino, i cijano, R7 je odabran iz grupe koja se sastoji od H, halo, hidroksila, okso, C1-C3 alkila, hidroksi-C1-C3-alkila, i halo-C1-C2-alkila, koji sadrži 1 do 5 halogena; n1, pri svakom pojavljivanju, je odabrano od 0, 1, 2 ili 3; i p, pri svakom pojavljivanju, je odabrano od 0, 1 i 2.
2. Spoj iz patentnog zahtjeva 1, ili stereoizomer, tautomer, farmaceutski prihvatljiva sol ili solvat istog, gdje: WjeO; R0 je R1; Y je S ili -CR8=CR9-; R1 je nezavisno odabran iz grupe koja se sastoji od: H, fluoro, kloro, C1-C2 alkila, C1-C2 alkoksi, C1-C2 alkiltio, i halo-C1-C2-alkila, koji sadrži 1 do 5 halogena, gdje halo je F ili Cl; R8 i R9 su nezavisno odabrani iz grupe koja se sastoji od: H, fluoro, kloro, CH3, OCH3, CF3, i CHF2; pod uvjetom da najmanje jedan od R1, R8 i R9 je drugačiji od H; R2 je H; X1 je odabran iz grupe koja se sastoji od CH ili N; X2 i X4 su CH; X3 je CR3; R3 je odabran iz grupe koja se sastoji od H, C1-C3 alkila, C1-C3 alkoksi, fluoro, kloro, OCF3, i halo-C1-C2-alkila, koji sadrži 1 do 5 halogena; R4 i R5 su nezavisno odabrani od H i metila; je 5-očlani heteroaril prsten odabran od tiazola, tiadiazola, oksazola, oksadiazola, i triazola; R6 je odabran iz grupe koja se sastoji od H, halo, OCF3, OCHF2, OH, NR11R12, C1-C4 alkoksikarbonila, (C=O)NR11R12 i C1-C5 alkila supstituiranog sa 0 do 7 grupa nezavisno odabranih od halo, CF3, OCF3, OH, hidroksi-C1-C4-alkila, C1-C4 alkoksi, C1-C4 alkoksi-C1-C4 alkoksi, di-C1-C4-alkilaminofenil-C1-C4-alkila, (di-C1-C4-alkoksi-C1-C4-alkil)-C1-C4-alkila, di-C1-C4-alkilamino, C3-C6-cikloalkila, i C1-C4 alkiltio, ili R6 je B-D-, gdje D je veznik, koji je odabran od: jednostruke veze, -O-, -S-,
C1-C4 alkilena supstituiranog sa 0 do 4 grupe nezavisno odabrane od halo ili OH, i C2-C6 alkenilena, i B je odabran iz grupe koja se sastoji od: C6-C10 arila supstituiranog sa 0 do 3 grupe nezavisno odabrane iz grupe koja se sastoji od halo, C1-C4 alkoksi, halo-C1-C4 alkoksi, C1-C4 alkila, halo-C1-C4 alkila, C3-C6 cikloalkila, cijano, nitro, NR11R12, OH, C1-C4-alkilkarboniloksi-C1-C4-alkila, hidroksi-C1-C4-alkila, COOR14, SO2R14, (C=O)NR11R12, SO2NR11R12, N(R13)(C=O)NR11R12, N(R13)(C=O)OR14, N(R13)(C=O)R14, NR13S(O)R14, NR13SO2R14, O(C=O)NR11R12, O(C=O)OR14, O(C=O)R14, (C=O)OR14, i 5-6-očlanog heteroarila, 5- do 10-očlanog heteroarila supstituiranog sa 0 do 3 grupe nezavisno odabrane iz grupe koja se sastoji od halo, C1-C4 alkoksi, halo-C1-C4 alkoksi, C1-C4 alkila, halo-C1-C4 alkila, C3-C6 cikloalkila, cijano, nitro, NR11R12, OH, C1-C4-alkilkarboniloksi-C1-C4-alkila, hidroksi-C1-C4-alkila, COOR14, SO2R14, (C=O)NR11R12, SO2NR11R12, N(R13)(C=O)NR11R12, N(R13)(C=O)OR14, N(R13)(C=O)R14, NR13S(O)R14, NR13SO2R14, O(C=O)NR11R12, O(C=O)OR14, O(C=O)R14, (C=O)OR14, 5-6-očlanog heteroarila, i (CH2)fenila, 4- do 10-očlanog heterociklila koji sadrži atome ugljika i 1 do 2 dodatna heteroatoma odabrana od N, O, i S, i supstituiranog sa 0 do 3 grupe nezavisno odabrane od grupe koja se sastoji od halo, okso, -(CHR13)n1-5- ili 6-očlanog heteroarila supstituiranog sa 0 do 3 grupe nezavisno odabrane iz grupe koja se sastoji od halo, C1-C4 alkoksi, C1-C4 alkila, ciklopropila, CF3, OCF3, i CF2CH3; NR13S(O)R14, NR13SO2R14, -(CHR13)n1-4- do 10-očlanog-heterociklila supstituiranog sa 0 do 3 grupe nezavisno odabrane iz grupe koja se sastoji od halo, C1-C4 alkoksi, C1-C4 alkila, ciklopropila, CF3, OCF3, i CF2CH3; OH, hidroksi-C1-C4-alkila, C1-C4 alkoksi, halo-C1-C4 alkoksi, di-C1-C4-alkilamino-C1-C4-alkila, NR11R12, cijano, C1-C4 alkila, halo-C1-C4 alkila, C3-C6 cikloalkila, C1-C4-alkoksi-C1-C4-alkila, C3-C6 cikloalkil-C1-C4-alkilkarbonila, C6-C10 arilkarbonila, C1-C4-alkilkarboniloksi-C1-C4-alkila, COOR14, SO2R14, (C=O)NR11R12, SO2NR11R12, N(R13)(C=O)NR11R12, N(R13)(C=O)OR14, N(R13)(C=O)R14, O(C=O)NR11R12, O(C=O)OR14, O(C=O)R14, (C=O)OR14, i C6-C10 arila supstituiranog sa 0 do 3 grupe nezavisno odabrane iz grupe koja se sastoji od halo, C1-C4 alkoksi, C1-C4 alkila, ciklopropila, C1-C4-alkoksikarbonila, (C=O)NR11R12, CF3, OCF3, i CF2CH3; i C3-C6 cikloalkila koji može da sadrži nezasićenje, supstituiranog sa 0 do 3 grupe nezavisno odabrane iz grupe koja se sastoji od halo, CF3, OCF3, 5- ili 6-očlanog heteroarila, OH, okso, hidroksi-C1-C4-alkila, C6-C10 arila, COOH, okso, C1-C4-alkoksikarbonila, (C=O)NR11R12, i C1-C4 alkila; R11 i R12 su nezavisno, pri svakom pojavljivanju, odabrani iz grupe koja se sastoji od: H, C1-C4 alkila, halo-C1-C4-alkila, C2-C4 alkenila, -(CR14R14)n1-fenila supstituiranog sa 0 do 3 grupe nezavisno odabrane iz grupe koja se sastoji od halo, C1-C4 alkoksi, C1-C4 alkila, ciklopropila, CF3, OCF3, 5- ili 6-očlanog heteroarila, OH, OCHF2, di-C1-C4-alkilamino, i cijano, -(CHR13)n1-C3-C6-cikloalkila supstituiranog sa 0 do 3 grupe nezavisno odabrane iz grupe koja se sastoji od halo, CF3, OCF3, 5- ili 6-očlanog heteroarila, OH, hidroksi-C1-C4-alkila, i C1-C4 alkila, -(CHR13)n1-4- do 10-očlanog-heterociklila supstituiranog sa 0 do 3 grupe nezavisno odabrane iz grupe koja se sastoji od halo, CF3, OCF3, 5- ili 6-očlanog heteroarila, OH, okso, hidroksi-C1-C4-alkila, i C1-C4 alkila, -(CHR13)n1-5- do 10-očlanog-heteroarila supstituiranog sa 0 do 3 grupe nezavisno odabrane iz grupe koja se sastoji od halo, CF3, OCF3, 5- ili 6-očlanog heteroarila, OH, hidroksi-C1-C4-alkila, i C1-C4 alkila, di-C1-C4-alkilamino-C1-C4-alkila, di-C1-C4-alkoksi-C1-C4-alkila, hidroksi-C1-C4-alkila, cijano-C1-C4-alkila, C1-C4-alkoksi-C1-C4-alkila, C1-C4-alkoksikarbonil-C1-C4-alkila, C1-C4-alkoksikarbonila, C1-C4-alkilkarbonila, i fenilkarbonila; alternativno, R11 i R12, kada su vezani za isti dušik, kombiniraju se da formiraju 4- do 8-očlani heterociklični prsten koji sadrži atome ugljika supstituirane sa 0 do 3 grupe nezavisno odabrane iz grupe koja se sastoji od halo, CF3, CHF2, OCF3, OCHF2, OCH2F, 5- ili 6-očlanog heteroarila, OH, okso, hidroksi-C1-C4-alkila, C1-C4 alkila i C1-C4 alkoksi, i 0 do 2 dodatna heteroatoma odabrana od N, NR13, O i S(O)p; R13 je nezavisno, pri svakom pojavljivanju, odabran iz grupe koja se sastoji od H, i C1-C3 alkila; R14 je nezavisno, pri svakom pojavljivanju, odabran iz grupe koja se sastoji od H, C1-C3 alkila, i halo-C1-C2-alkila; R7 je odabran iz grupe koja se sastoji od H, fluoro, kloro, okso, C1-C3 alkila, hidroksi-C1-C3-alkila, i halo-C1-C2-alkila, koji sadrži 1 do 5 halogena; n1, pri svakom pojavljivanju, je odabrano od 0, 1, 2 ili 3; i p, pri svakom pojavljivanju, je odabrano od 0, 1 i 2.
3. Spoj iz patentnog zahtjeva 1, ili stereoizomer, tautomer, farmaceutski prihvatljiva sol ili solvat istog, gdje: WjeO; R0 je R1; Y je S ili -CH=CH-; R1 je nezavisno odabran iz grupe koja se sastoji od: kloro, CH3, OCH3, SCH3, CHFCH3, i CF2CH3; R2 je H; X1 je CH; X2 i X4 su CH; X3 je CR3; R3 je odabran iz grupe koja se sastoji od OCH3, fluoro, i kloro; R4 i R5 su nezavisno odabrani od H i CH3; je 5-očlani heteroaril prsten odabran od tiazola i oksazola; R6 je odabran iz grupe koja se sastoji od, NR11R12, i C1-C5 alkila supstituiranog sa 0 do 3 grupe nezavisno odabrane od halo, CF3, OCF3, OH, hidroksi-C1-C4-alkila, C1-C4 alkoksi, C1-C4 alkoksi-C1-C4 alkoksi, di-C1-C4-alkilaminofenil-C1-C4-alkila, (di-C1-C4-alkoksi-C1-C4-alkil)-C1-C4-alkila, di-C1-C4-alkilamino, C3-C6-cikloalkila, i C1-C4 alkiltio, ili R6 je B-D-, gdje D je jednostruka veza; B je odabran iz grupe koja se sastoji od: C6-C10 arila supstituiranog sa 0 do 3 grupe nezavisno odabrane iz grupe koja se sastoji od halo, C1-C4 alkoksi, halo-C1-C4 alkoksi, C1-C4 alkila, halo-C1-C4 alkila, C3-C6 cikloalkila, cijano, nitro, NR11R12, OH, C1-C4-alkilkarboniloksi-C1-C4-alkila, hidroksi-C1-C4-alkila, COOR14, SO2R14, (C=O)NR11R12, SO2NR11R12, N(R13)(C=O)NR11R12, N(R13)(C=O)OR14, N(R13)(C=O)R14, NR13S(O)R14, NR13SO2R14, O(C=O)NR11R12, O(C=O)OR14, O(C=O)R14, (C=O)OR14, i 5-6-očlanog heteroarila, 5- do 10-očlanog heteroarila supstituiranog sa 0 do 3 grupe nezavisno odabrane iz grupe koja se sastoji od halo, C1-C4 alkoksi, halo-C1-C4 alkoksi, C1-C4 alkila, halo-C1-C4 alkila, C3-C6 cikloalkila, cijano, nitro, NR11R12, OH, C1-C4-alkilkarboniloksi-C1-C4-alkila, hidroksi-C1-C4-alkila, COOR14, SO2R14, (C=O)NR11R12, SO2NR11R12, N(R13)(C=O)NR11R12, N(R13)(C=O)OR14, N(R13)(C=O)R14, NR13S(O)R14, NR13SO2R14, O(C=O)NR11R12, O(C=O)OR14, O(C=O)R14, (C=O)OR14, 5-6-očlanog heteroarila, i (CH2)fenila, 4- do 10-očlanog heterociklila koji sadrži atome ugljika i 1 do 2 dodatna heteroatoma odabrana od N, O, i S, i supstituiranog sa 0 do 3 grupe nezavisno odabrane iz grupe koja se sastoji od halo, okso, -(CHR13)n1-5- ili 6-očlanog heteroarila supstituiranog sa 0 do 3 grupe nezavisno odabrane iz grupe koja se sastoji od halo, C1-C4 alkoksi, C1-C4 alkila, ciklopropila, CF3, OCF3, i CF2CH3; NR13S(O)R14, NR13SO2R14, -(CHR13)n1-4- do 10-očlanog-heterociklila supstituiranog sa 0 do 3 grupe nezavisno odabrane iz grupe koja se sastoji od halo, C1-C4 alkoksi, C1-C4 alkila, ciklopropila, CF3, OCF3, i CF2CH3; OH, hidroksi-C1-C4-alkila, C1-C4 alkoksi, halo-C1-C4 alkoksi, di-C1-C4-alkilamino-C1-C4-alkila, NR11R12, cijano, C1-C4 alkila, halo-C1-C4 alkila, C3-C6 cikloalkila, C1-C4-alkoksi-C1-C4-alkila, C3-C6 cikloalkil-C1-C4-alkilkarbonila, C6-C10 arilkarbonila, C1-C4-alkilkarboniloksi-C1-C4-alkila, COOR14, SO2R14, (C=O)NR11R12, SO2NR11R12, N(R13)(C=O)NR11R12, N(R13)(C=O)OR14, N(R13)(C=O)R14, O(C=O)NR11R12, O(C=O)OR14, O(C=O)R14, (C=O)OR14, i C6-C10 arila supstituiranog sa 0 do 3 grupe nezavisno odabrane iz grupe koja se sastoji od halo, C1-C4 alkoksi, C1-C4 alkila, ciklopropila, C1-C4-alkoksikarbonila, (C=O)NR11R12, CF3, OCF3, i CF2CH3; i C3-C6 cikloalkila koji može da sadrži nezasićenje, supstituiranog sa 0 do 3 grupe nezavisno odabrane iz grupe koja se sastoji od halo, CF3, OCF3, 5- ili 6-očlanog heteroarila, OH, okso, hidroksi-C1-C4-alkila, C6-C10 arila, COOH, okso, C1-C4-alkoksikarbonila, (C=O)NR11R12, i C1-C4 alkila; R11 i R12 su nezavisno, pri svakom pojavljivanju, odabrani iz grupe koja se sastoji od: H, C1-C4 alkila, halo-C1-C4-alkila, di-C1-C4-alkilamino-C1-C4-alkila, di-C1-C4-alkoksi-C1-C4-alkila, hidroksi-C1-C4-alkila, cijano-C1-C4-alkila, C1-C4-alkoksi-C1-C4-alkila, C1-C4-alkoksikarbonil-C1-C4-alkila, i C1-C4-alkoksikarbonila; alternativno, R11 i R12, kada su vezani za isti dušik, kombiniraju se da formiraju 4- do 7-očlani heterociklični prsten koji sadrži atome ugljika supstituirane sa 0 do 2 grupe nezavisno odabrane iz grupe koja se sastoji od halo, CF3, CHF2, OCF3, OCHF2, OCH2F, OH, okso, hidroksi-C1-C2-alkila, C1-C3 alkila i C1-C3 alkoksi, i 0 do 2 dodatna heteroatoma odabrana od N, NR13, O i S(O)p; R13 je nezavisno, pri svakom pojavljivanju, odabran iz grupe koja se sastoji od H, i C1-C3 alkila; R14 je nezavisno, pri svakom pojavljivanju, odabran iz grupe koja se sastoji od H, i C1-C3 alkila R7 je odabran iz grupe koja se sastoji od H, fluoro, kloro, C1-C3 alkila, hidroksi-C1-C3-alkila, i halo-C1-C2-alkila, koji sadrži 1 do 5 halogena; n1, pri svakom pojavljivanju, je odabrano od 0, 1, 2 ili 3; i p, pri svakom pojavljivanju, je odabrano od 0, 1 i 2.
4. Spoj iz patentnog zahtjeva 1 koje ima Formulu:
5. Spoj iz patentnog zahtjeva 1 koje ima Formulu:
6. Spoj iz patentnog zahtjeva 1 koje ima Formulu:
7. Spoj iz patentnog zahtjeva 1 koje ima Formulu:
8. Farmaceutska kompozicija, koja sadrži farmaceutski prihvatljiv nosač i spoj kao što je definirano u bilo kojem od patentnih zahtjeva 1 do 3, ili stereoizomere, tautomere, farmaceutski prihvatljive soli, ili solvate istog, zasebno ili u kombinaciji sa drugim terapijskim agensom.
9. Farmaceutska kompozicija, koja sadrži farmaceutski prihvatljiv nosač i spoj kao što je definirano u bilo kojem od patentnih zahtjeva 4 do 7, zasebno ili u kombinaciji sa drugim terapijskim agensom.
10. Spoj kao što je definirano u bilo kojem od patentnih zahtjeva 1 do 3, ili stereoizomeri, tautomeri, farmaceutski prihvatljive soli, ili solvati istog, za primjenu u terapiji.
11. Spoj kao što je definirano u bilo kojem od patentnih zahtjeva 1 do 3, ili stereoizomeri, tautomeri, farmaceutski prihvatljive soli, ili solvati istog, za primjenu u liječenju tromboembolijskog poremećaja ili primarnoj ili sekundarnoj profilaksi tromboembolijskog poremećaja.
12. Spoj za primjenu kao što je definirano u patentnom zahtjevu 11, gdje je tromboembolijski poremećaj odabran iz grupe koja se sastoji od arterijskih kardiovaskularnih tromboembolijskih poremećaja, venskih kardiovaskularnih tromboembolijskih poremećaja, cerebrovaskularnih tromboembolijskih poremećaja, i tromboembolijskih poremećaja u komorama srca ili u perifernoj cirkulaciji.
13. Spoj kao što je definirano u bilo kojem od patentnih zahtjeva 4 do 7 za primjenu u terapiji.
14. Spoj kao što je definirano u bilo kojem od patentnih zahtjeva 4 do 7 za primjenu u liječenju tromboembolijskog poremećaja ili primarnoj ili sekundarnoj profilaksi tromboembolijskog poremećaja.
15. Spoj za primjenu kao što je definirano u patentnom zahtjevu 14, gdje tromboembolijski poremećaj je odabran iz grupe koja se sastoji od arterijskih kardiovaskularnih tromboembolijskih poremećaja, venskih kardiovaskularnih tromboembolijskih poremećaja, cerebrovaskularnih tromboembolijskih poremećaja, i tromboembolijskih poremećaja u komorama srca ili u perifernoj cirkulaciji.
HRP20192336TT 2012-04-26 2019-12-30 Derivati imidazotiadiazola i imidazopirazina kao inhibitori proteazom aktiviranog receptora 4 (par4) za liječenje agregacije trombocita HRP20192336T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261638577P 2012-04-26 2012-04-26
US201361787680P 2013-03-15 2013-03-15
EP17172927.0A EP3243826B1 (en) 2012-04-26 2013-04-24 Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation

Publications (1)

Publication Number Publication Date
HRP20192336T1 true HRP20192336T1 (hr) 2020-03-20

Family

ID=48407806

Family Applications (3)

Application Number Title Priority Date Filing Date
HRP20221495TT HRP20221495T1 (hr) 2012-04-26 2013-04-24 Farmaceutske kompozicije koje sadrže derivate imidazotiadiazola i imidazopiridazina kao inhibitore proteazom aktiviranih receptora 4 (par4) za liječenje agregacije trombocita
HRP20171453TT HRP20171453T1 (hr) 2012-04-26 2017-09-28 Derivati imidazotiadiazola i imidazopirazina kao inhibitori proteazom aktiviranog receptora 4 (par4) za liječenje agregacije trombocita
HRP20192336TT HRP20192336T1 (hr) 2012-04-26 2019-12-30 Derivati imidazotiadiazola i imidazopirazina kao inhibitori proteazom aktiviranog receptora 4 (par4) za liječenje agregacije trombocita

Family Applications Before (2)

Application Number Title Priority Date Filing Date
HRP20221495TT HRP20221495T1 (hr) 2012-04-26 2013-04-24 Farmaceutske kompozicije koje sadrže derivate imidazotiadiazola i imidazopiridazina kao inhibitore proteazom aktiviranih receptora 4 (par4) za liječenje agregacije trombocita
HRP20171453TT HRP20171453T1 (hr) 2012-04-26 2017-09-28 Derivati imidazotiadiazola i imidazopirazina kao inhibitori proteazom aktiviranog receptora 4 (par4) za liječenje agregacije trombocita

Country Status (36)

Country Link
US (5) US9688695B2 (hr)
EP (3) EP2841437B1 (hr)
JP (1) JP6073464B2 (hr)
KR (3) KR102098804B1 (hr)
CN (2) CN108383858B (hr)
AR (1) AR090834A1 (hr)
AU (1) AU2013251632B2 (hr)
BR (1) BR112014026643B1 (hr)
CA (1) CA2871650C (hr)
CL (1) CL2014002915A1 (hr)
CO (1) CO7160040A2 (hr)
CY (2) CY1119466T1 (hr)
DK (3) DK2841437T3 (hr)
EA (1) EA026724B1 (hr)
ES (3) ES2935173T3 (hr)
FI (1) FI3632919T3 (hr)
HK (1) HK1203953A1 (hr)
HR (3) HRP20221495T1 (hr)
HU (3) HUE048654T2 (hr)
IL (1) IL235246B (hr)
LT (2) LT3632919T (hr)
MX (1) MX354175B (hr)
MY (1) MY175061A (hr)
NZ (1) NZ631027A (hr)
PE (1) PE20142285A1 (hr)
PH (1) PH12014502173A1 (hr)
PL (3) PL3243826T3 (hr)
PT (3) PT3632919T (hr)
RS (3) RS59882B1 (hr)
SG (1) SG11201406757SA (hr)
SI (3) SI3243826T1 (hr)
TN (1) TN2014000436A1 (hr)
TW (1) TWI572605B (hr)
UY (1) UY34763A (hr)
WO (1) WO2013163279A1 (hr)
ZA (1) ZA201407799B (hr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014026493A2 (pt) 2012-04-26 2017-06-27 Bristol Myers Squibb Co derivados de imidazotiadiazol como inibidores do receptor ativado por protease 4 (par4) para tratar a agregação de plaqueta
PL3243826T3 (pl) * 2012-04-26 2020-08-24 Bristol-Myers Squibb Company Pochodne imidazotiadiazolu i imidazopirazyny jako inhibitory receptora 4 (par4) aktywowanego proteazą do leczenia agregacji płytek
BR112014026651A8 (pt) 2012-04-26 2018-01-16 Bristol Myers Squibb Co derivados de imidazotiadiazol e de imidazopiridazina como inibidores do receptor ativado por proteases 4 (par4) para o tratamento de agregação plaquetária
TWI568722B (zh) 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
US9278950B2 (en) 2013-01-14 2016-03-08 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
NZ749911A (en) 2013-01-15 2020-02-28 Incyte Holdings Corp Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
MX2016002367A (es) 2013-08-23 2016-10-28 Incyte Corp Compuestos de carboxamida de furo y tienopiridina utiles como inhibidores de cinasas pim.
US9598419B1 (en) 2014-06-24 2017-03-21 Universite De Montreal Imidazotriazine and imidazodiazine compounds
US9617279B1 (en) 2014-06-24 2017-04-11 Bristol-Myers Squibb Company Imidazooxadiazole compounds
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
US10214544B2 (en) 2015-02-26 2019-02-26 Universite De Montreal Imidazopyridazine and imidazothiadiazole compounds
WO2016138199A1 (en) 2015-02-26 2016-09-01 Bristol-Myers Squibb Company Benzothiazole and benzothiophne compounds
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
US9789087B2 (en) 2015-08-03 2017-10-17 Thomas Jefferson University PAR4 inhibitor therapy for patients with PAR4 polymorphism
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Ｐｉｍ激酶抑制劑之鹽
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
EP3371196B1 (en) 2015-10-19 2021-10-27 Université de Montréal Heterocyclic compounds as inhibitors of platelet aggregation
US9963466B2 (en) 2016-03-07 2018-05-08 Vanderbilt University Substituted 5-membered heterocyclic analogs as protease activated receptor 4 (PAR-4) antagonists
WO2017184520A1 (en) * 2016-04-18 2017-10-26 Vanderbilt University Substituted and fused 6-membered protease activated receptor 4 (par-4) antagonists
WO2018013776A1 (en) 2016-07-14 2018-01-18 Bristol-Myers Squibb Company Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as par4 inhibitors
WO2018013770A1 (en) 2016-07-14 2018-01-18 Bristol-Myers Squibb Company Bicyclic heteroaryl substituted compounds
CN109689642B (zh) 2016-07-14 2022-04-12 百时美施贵宝公司 经单环杂芳基取代的化合物
WO2018013774A1 (en) 2016-07-14 2018-01-18 Bristol-Myers Squibb Company Bicyclic heteroaryl substituted compounds
CN108239083B (zh) 2016-12-26 2021-08-17 阿里根公司 芳香烃受体调节剂
EP3713937A2 (en) 2017-11-20 2020-09-30 Ariagen, Inc. Indole compounds as aryl hydrocarbon receptor (ahr) modulators
TW201924683A (zh) 2017-12-08 2019-07-01 美商英塞特公司 用於治療骨髓增生性贅瘤的低劑量組合療法
WO2019149205A1 (zh) * 2018-01-31 2019-08-08 江苏恒瑞医药股份有限公司 苯并杂芳基类衍生物、其制备方法及其在医药上的应用
CN110218218B (zh) * 2018-03-01 2022-04-08 江苏恒瑞医药股份有限公司 苯并呋喃类衍生物、其制备方法及其在医药上的应用
CN110272436A (zh) * 2018-03-14 2019-09-24 中国药科大学 氘代的咪唑并噻二唑衍生物及其医药用途
WO2019218956A1 (zh) * 2018-05-16 2019-11-21 深圳信立泰药业股份有限公司 作为用于治疗血小板聚集的蛋白酶激活受体4(par4)抑制剂的化合物
CN112074522B (zh) * 2018-05-16 2022-08-26 深圳信立泰药业股份有限公司 作为用于治疗血小板聚集的蛋白酶激活受体4(par4)抑制剂的化合物
CN110627817B (zh) * 2018-06-25 2022-03-29 中国药科大学 咪唑并环类par4拮抗剂及其医药用途
KR20210052435A (ko) * 2018-08-30 2021-05-10 니혼 메디피직스 가부시키가이샤 방사성 이미다조티아디아졸 유도체 화합물
TW202038943A (zh) 2018-11-19 2020-11-01 美商雅里俊公司 治療癌症之方法
WO2020132381A1 (en) * 2018-12-21 2020-06-25 Bristol-Myers Squibb Company Crystalline forms of a par4 inhibitor
CN111349105B (zh) * 2018-12-24 2023-04-07 江苏恒瑞医药股份有限公司 苯并呋喃类衍生物、其制备方法及其在医药上的应用
CN111362970A (zh) * 2018-12-25 2020-07-03 天津药物研究院有限公司 苯并呋喃类衍生物及其制备方法和用途
KR20210151951A (ko) 2019-04-15 2021-12-14 아리아젠, 인크. 키랄 인돌 화합물 및 그 용도
EP3782702A1 (en) * 2019-08-21 2021-02-24 AC BioScience SA Compounds and use thereof for the treatment of infectious diseases and cancer
CN112079791A (zh) * 2020-08-21 2020-12-15 宁夏农林科学院农业资源与环境研究所（宁夏土壤与植物营养重点实验室） 单环β-内酰胺类抗生素侧链酸及其酯、其制备方法和应用
CN113150005B (zh) * 2021-04-09 2022-08-30 中国药科大学 喹喔啉类化合物、制备方法及其在医药上的应用
US12077607B2 (en) 2021-09-23 2024-09-03 University Of Utah Research Foundation Functional and therapeutic effects of PAR4 cleavage by cathepsin G

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2823686A1 (de) * 1978-05-31 1979-12-06 Bayer Ag Imidazo eckige klammer auf 2.1-b eckige klammer zu eckige klammer auf 1.3.4 eckige klammer zu -thiadiazole
US4444770A (en) 1980-05-29 1984-04-24 Bayer Aktiengesellschaft New imidazoazole-alkenoic acid amide compounds, intermediate products for their production, their production, and their medicinal use
DE3020421A1 (de) 1980-05-29 1981-12-10 Bayer Ag, 5090 Leverkusen Imidazoazolalkensaeureamide, neue zwischenprodukte zu ihrer herstellung, ihre herstellung und ihre verwendung in arzneimitteln
DE3446778A1 (de) 1984-12-21 1986-07-03 Dr. Karl Thomae Gmbh, 7950 Biberach Neue imidazoderivate, ihre herstellung und diese verbindungen enthaltende arzneimittel
US4925849A (en) 1987-06-15 1990-05-15 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutically useful pyrazolopyridines
GB8901423D0 (en) 1989-01-23 1989-03-15 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof
CA2060138A1 (en) 1991-01-29 1992-07-30 Youichi Shiokawa New use of the adenosine antagonist
US5342851A (en) * 1992-10-07 1994-08-30 Mcneil-Ppc, Inc. Substituted thiazole derivatives useful as platelet aggregation inhibitors
JP2928079B2 (ja) 1994-02-14 1999-07-28 永信薬品工業股▲ふん▼有限公司 １−（置換ベンジル）−３−（置換アリール）縮合ピラゾール類、その製造法及びその用途
ATE451346T1 (de) 1998-03-10 2009-12-15 Ono Pharmaceutical Co Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten
DE19948434A1 (de) 1999-10-08 2001-06-07 Gruenenthal Gmbh Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine
AU781227B2 (en) 1999-10-08 2005-05-12 Grunenthal Gmbh Bicyclic imidazo-5-yl-amine derivatives
DE10019714A1 (de) 2000-04-20 2002-01-10 Gruenenthal Gmbh Salze von bicyclischen, N-acylierten Imidazo-3-aminen und Imidazo-5-aminen
US6387942B2 (en) 2000-06-19 2002-05-14 Yung Shin Pharmaceutical Ind. Co. Ltd Method of treating disorders related to protease-activated receptors-induced cell activation
WO2003040114A1 (en) 2001-11-06 2003-05-15 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
CA2364985A1 (en) 2001-12-14 2003-06-14 John W. Gillard Imidazo(2,1-b)thiadiazole sulfonamides
EP1582516B1 (en) 2003-01-10 2013-07-17 Idemitsu Kosan Co., Ltd. Nitrogenous heterocyclic derivative and organic electroluminescent element employing the same
EP1636241A1 (en) 2003-06-13 2006-03-22 Aegera Therapeutics Inc. Imidazo (2,1-b) -1,3,4-thiadiazole sulfoxides and sulfones
WO2004111061A1 (en) 2003-06-13 2004-12-23 Aegera Therapeutics Inc. ACYLATED AND NON-ACYLATED IMIDAZO[2,1-b]-1,3,4,-THIADIAZOLE-2-SULFONAMIDES, AND USES THEREOF
WO2005041959A1 (en) 2003-10-31 2005-05-12 Janssen Pharmaceutica N.V. Phenoxyacetic acids derivatives useful as peroxisome proliferator-activated receptor (ppar) dual agonists
JP2007512255A (ja) 2003-11-13 2007-05-17 アンビット バイオサイエンシス コーポレーション キナーゼ調節因子としての尿素誘導体
CA2555263A1 (en) 2004-02-12 2005-09-01 Neurogen Corporation Imidazo-pyridazines, triazolo-pyridazines and related benzodiazepine receptor ligands
WO2006109846A1 (ja) * 2005-04-06 2006-10-19 Takeda Pharmaceutical Company Limited トリアゾール誘導体およびその用途
EP1893245A4 (en) 2005-06-24 2009-06-24 Univ Pennsylvania RADIOACTIVELY MARKED PEGYLATION OF LIGANDS FOR USE AS A CONTRAST
WO2007039177A2 (en) 2005-09-29 2007-04-12 Sanofi-Aventis Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
NL2000397C2 (nl) 2006-01-05 2007-10-30 Pfizer Prod Inc Bicyclische heteroarylverbindingen als PDE10 inhibitoren.
EP2001844A2 (en) 2006-03-14 2008-12-17 Amgen, Inc Bicyclic carboxylic acid derivatives useful for treating metabolic disorders
BRPI0710133A2 (pt) 2006-04-13 2012-10-30 Aegera Therapeutics Inc uso de compostos de imidazo[2,1-b]-1,3,4-tiadiazol-2-sulfonamida para tratar dor neuropática
DE102006054757A1 (de) 2006-11-21 2008-05-29 Bayer Healthcare Ag Neue aza-bicyclische Verbindungen und ihre Verwendung
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
EP1964841A1 (en) 2007-02-28 2008-09-03 sanofi-aventis Imidazo[1,2-a]azine and their use as pharmaceuticals
CN101855222A (zh) 2007-05-10 2010-10-06 通用电气健康护理有限公司 对大麻素cb2受体具有活性的咪唑并(1,2-a)吡啶和相关化合物
WO2009017954A1 (en) 2007-08-01 2009-02-05 Phenomix Corporation Inhibitors of jak2 kinase
BRPI0814939A2 (pt) 2007-08-10 2015-01-27 Glaxosmithkline Llc Entidade química, composição farmacêutica, e, método para tratar uma infecção viral em um mamífero.
WO2009027733A1 (en) 2007-08-24 2009-03-05 Astrazeneca Ab (2-pyridin-3-ylimidazo[1,2-b]pyridazin-6-yl) urea derivatives as antibacterial agents
GB0718735D0 (en) 2007-09-25 2007-11-07 Prolysis Ltd Antibacterial agents
CA2710016A1 (en) 2007-12-21 2009-07-02 The University Of Sydney Translocator protein ligands
DK2280704T3 (en) 2008-03-31 2015-06-29 Cymabay Therapeutics Inc Oxymethylenarylforbindelser and uses thereof
CN102159582B (zh) 2008-07-15 2014-05-07 赛诺菲-安万特 作为Edg-1受体激动剂的噁唑并嘧啶
EP2331530B8 (en) 2008-09-26 2013-12-25 National Health Research Institutes Fused multicyclic compounds as protein kinase inhibitors
MX2011006332A (es) 2008-12-23 2011-06-27 Abbott Lab Compuestos antivirales.
TWI504600B (zh) 2009-12-18 2015-10-21 Mitsubishi Tanabe Pharma Corp 新穎抗血小板藥
CN102372701A (zh) 2010-08-10 2012-03-14 江苏恒瑞医药股份有限公司 氮杂双环己烷类衍生物、其制备方法及其在医药上的应用
EP2603214A4 (en) 2010-08-11 2013-12-18 Millennium Pharm Inc HETEROARYLE AND USES THEREOF
AU2012298983A1 (en) 2011-08-22 2014-02-27 Merck Sharp & Dohme Corp. 2-spiro-substituted iminothiazines and their mono-and dioxides as BACE inhibitors, compositions and their use
CA2871640A1 (en) * 2012-04-26 2013-10-31 Bristol-Myers Squibb Company Par4 agonist peptides
BR112014026493A2 (pt) 2012-04-26 2017-06-27 Bristol Myers Squibb Co derivados de imidazotiadiazol como inibidores do receptor ativado por protease 4 (par4) para tratar a agregação de plaqueta
PL3243826T3 (pl) 2012-04-26 2020-08-24 Bristol-Myers Squibb Company Pochodne imidazotiadiazolu i imidazopirazyny jako inhibitory receptora 4 (par4) aktywowanego proteazą do leczenia agregacji płytek
BR112014026651A8 (pt) * 2012-04-26 2018-01-16 Bristol Myers Squibb Co derivados de imidazotiadiazol e de imidazopiridazina como inibidores do receptor ativado por proteases 4 (par4) para o tratamento de agregação plaquetária
BR112014026760A8 (pt) 2012-04-27 2018-01-16 Novartis Ag inibidores de éter cabeça de ponte cíclico dgat1
MY169377A (en) 2012-05-15 2019-03-26 Novartis Ag Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
US9109001B2 (en) 2012-05-22 2015-08-18 Idenix Pharmaceuticals, Inc. 3′,5′-cyclic phosphoramidate prodrugs for HCV infection
TWI568722B (zh) 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
DK2864350T3 (en) 2012-06-21 2018-05-28 Univ Indiana Res & Tech Corp ANALOGUE OF GLUCAGON EXPRESSING GIP RECEPTOR ACTIVITY
AR092348A1 (es) 2012-07-11 2015-04-15 Hoffmann La Roche DERIVADOS DE ARIL-SULTAMO COMO MODULADORES DE RORc
TW201414737A (zh) 2012-07-13 2014-04-16 必治妥美雅史谷比公司 作爲激酶抑制劑之咪唑并三□甲腈
CN104718213B (zh) 2012-07-18 2018-02-27 圣母大学 5,5‑杂芳族抗感染化合物
TW201422592A (zh) 2012-08-27 2014-06-16 Boehringer Ingelheim Int β－分泌酶抑制劑
UA114531C2 (uk) 2012-10-16 2017-06-26 ЯНССЕН САЙЄНСІЗ АЙРЛЕНД ЮСі Противірусні сполуки проти rsv
US9630945B2 (en) 2012-12-19 2017-04-25 Novartis Ag Autotaxin inhibitors
KR102120875B1 (ko) 2012-12-21 2020-06-09 길리애드 사이언시즈, 인코포레이티드 폴리시클릭-카르바모일피리돈 화합물 및 그의 제약 용도

Also Published As

Publication number Publication date
US12084452B2 (en) 2024-09-10
WO2013163279A1 (en) 2013-10-31
AU2013251632A1 (en) 2014-11-13
DK3243826T3 (da) 2020-02-03
PT2841437T (pt) 2017-09-28
BR112014026643B1 (pt) 2023-03-07
RS56395B1 (sr) 2017-12-29
KR20200040308A (ko) 2020-04-17
AR090834A1 (es) 2014-12-10
CN108383858A (zh) 2018-08-10
KR102176379B1 (ko) 2020-11-09
US9688695B2 (en) 2017-06-27
US10428077B2 (en) 2019-10-01
MX354175B (es) 2018-02-16
HK1203953A1 (en) 2015-11-06
DK2841437T3 (en) 2017-10-23
PL3632919T3 (pl) 2023-02-20
HRP20171453T1 (hr) 2017-11-17
CN104583218B (zh) 2018-04-24
US10047103B2 (en) 2018-08-14
EP3243826A1 (en) 2017-11-15
CY1119466T1 (el) 2018-03-07
CL2014002915A1 (es) 2015-02-13
EP2841437A1 (en) 2015-03-04
EP3243826B1 (en) 2019-10-30
DK3632919T3 (da) 2022-11-14
FI3632919T3 (fi) 2023-01-13
BR112014026643A8 (pt) 2021-06-15
CN104583218A (zh) 2015-04-29
PH12014502173B1 (en) 2014-12-10
CA2871650C (en) 2017-09-19
UY34763A (es) 2013-10-31
CA2871650A1 (en) 2013-10-31
EA201491968A1 (ru) 2015-05-29
CY1122625T1 (el) 2021-03-12
HUE034566T2 (hu) 2018-02-28
EP3632919A1 (en) 2020-04-08
SI3243826T1 (sl) 2020-03-31
US10822343B2 (en) 2020-11-03
PE20142285A1 (es) 2015-01-08
LT2841437T (lt) 2017-09-11
MX2014012296A (es) 2015-01-14
PT3243826T (pt) 2020-01-28
ES2935173T3 (es) 2023-03-02
MY175061A (en) 2020-06-04
SI2841437T1 (sl) 2017-09-29
EP2841437B1 (en) 2017-07-05
US20200123160A1 (en) 2020-04-23
HUE060743T2 (hu) 2023-04-28
KR20200127273A (ko) 2020-11-10
PL3243826T3 (pl) 2020-08-24
ES2640916T3 (es) 2017-11-07
HRP20221495T1 (hr) 2023-02-03
EP3632919B1 (en) 2022-10-26
BR112014026643A2 (pt) 2017-06-27
PH12014502173A1 (en) 2014-12-10
EA026724B1 (ru) 2017-05-31
IL235246B (en) 2018-11-29
US20230242535A1 (en) 2023-08-03
KR102098804B1 (ko) 2020-04-08
RS63975B1 (sr) 2023-03-31
US20150094297A1 (en) 2015-04-02
LT3632919T (lt) 2023-02-27
PL2841437T3 (pl) 2017-12-29
CN108383858B (zh) 2024-09-20
TN2014000436A1 (en) 2016-03-30
TW201350487A (zh) 2013-12-16
NZ631027A (en) 2016-03-31
TWI572605B (zh) 2017-03-01
CO7160040A2 (es) 2015-01-15
RS59882B1 (sr) 2020-03-31
JP6073464B2 (ja) 2017-02-01
SI3632919T1 (sl) 2023-02-28
US20170247395A1 (en) 2017-08-31
SG11201406757SA (en) 2014-11-27
US20180305376A1 (en) 2018-10-25
JP2015514808A (ja) 2015-05-21
HUE048654T2 (hu) 2020-08-28
ZA201407799B (en) 2015-12-23
ES2770026T3 (es) 2020-06-30
AU2013251632B2 (en) 2016-12-15
KR20150009532A (ko) 2015-01-26
PT3632919T (pt) 2023-01-06

Similar Documents

Publication Publication Date Title
HRP20192336T1 (hr) Derivati imidazotiadiazola i imidazopirazina kao inhibitori proteazom aktiviranog receptora 4 (par4) za liječenje agregacije trombocita
PH12016501440A1 (en) Novel heterocyclic compounds
PH12020551315A1 (en) Benzoxazepin oxazolidinone compounds and methods of use
TR201910730T4 (tr) Yeni pirazolo pirimidin deriveleri ve bunların malt1 inhibitörleri olarak kullanımı.
RU2018121499A (ru) Гипоксантины в качестве ингибиторов убиквитин-специфической протеазы 1
PE20181144A1 (es) Derivados de heteroarilo como inhibidores de parp
AR064154A1 (es) Compuestos inhibidores de fodfoinostida 3- quinasas y composiciones farmaceuticas
RU2016146365A (ru) Новые дигидрохинолизиноны для лечения и профилактики заражения вирусом гепатита b
IL272762B1 (en) Compressed heterocyclics as BCL-2 inhibitors for the treatment of neoplastic diseases
EA201692267A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
EA201691471A1 (ru) Макроциклы с гетероциклическими группами p2' как ингибиторы фактора xia
JP2016530262A5 (hr)
EA201692249A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
AR081058A1 (es) Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer.
EA201692268A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
MX2016016538A (es) Derivados de quinazolinona como inhibidores de fosfatidilinositol 3-cinasa.
JO3398B1 (ar) مشتقات 2،3- ثانى هيدرو- بنزو[1,4] أوكسازين والمركبات المتعلقة بها كمثبطات كيناز فسفواينوسيتيد-3 (pi3k) لمعالجة على سبيل المثال التهاب المفاصل الروماتيدي
EA201101566A1 (ru) Производные имидазола и их применение в качестве модуляторов циклинзависимых киназ
PE20161369A1 (es) Inhibidores de monoacilglicerol aciltransferasa 2 (mgat2) de dihidropiridinona sustituidos con tetrazolona
EA022420B1 (ru) Гетероциклические ингибиторы глутаминилциклазы (qc, ec 2.3.2.5)
EA201590022A1 (ru) Новые производные 1,3-дигидро-2h-бензимидазол-2-она, замещенные гетероциклами, в качестве противовирусных средств против респираторного синцитиального вируса
RU2017134110A (ru) Производное пиразола, пригодное в качестве ингибитора рi3к
HRP20240155T1 (hr) Spojevi i pripravci za induciranje hondrogeneze
HRP20210857T1 (hr) Derivati 2-(1,2,4-triazol-3-ilsulfanil)-n-1,3,4-tiadiazol-2-il acetamida koji su korisni za liječenje dijabetesa
IL274550B2 (en) Dopamine-b-hydroxylase inhibitors